Understand the source comparison
Best Peptides for Degenerative Disc Disease: Compound Comparison
BPC-157 VEGF upregulation, collagen deposition, FAK-paxillin pathway modulation 10 mcg/kg daily (rodent studies) 28 days refrigerated; degrades 40% in 7 days at room temp No human pharmacokinetic data; subcutaneous bioavailability to disc tissue unproven Most
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, collagen deposition, FAK-paxillin pathway modulation
- 10 mcg/kg daily (rodent studies)
- 28 days refrigerated; degrades 40% in 7 days at room temp
- No human pharmacokinetic data; subcutaneous bioavailability to disc tissue unproven
- Most studied for tendon/ligament repair; disc-specific trials absent
- TB-500
- Actin polymerisation inhibition, progenitor cell migration, anti-inflammatory
- Loading: 10mg 2x/week × 4 weeks; Maintenance: 5mg weekly (extrapolated)
- 28 days refrigerated; half-life ~10 days in vivo
- Large molecular weight (4963 Da) limits tissue penetration; no disc-specific human trials
- Strong cell migration data; mechanism relevant but delivery unvalidated
- GHK-Cu
- Glycosaminoglycan synthesis, MMP inhibition, TIMP upregulation, anti-inflammatory
- 1–3mg 2–3x/week (extrapolated from plasma restoration goals)
- 28 days refrigerated; requires 1:1 copper complexation before use
- Smaller size (340 Da) aids penetration, but no disc tissue concentration studies in humans
- Dual synthesis + anti-degradation action is mechanistically ideal; clinical proof lacking